This document describes a study that uses support vector machines (SVM) to develop quantitative structure-activity relationship (QSAR) models for predicting the anti-HIV activity of 1,3,4-oxadiazole substituted naphthyridine derivatives based on their molecular descriptors. The SVM model achieved a cross-validation R2 value of 0.90 and RMSE of 0.145, outperforming artificial neural network and multiple linear regression models. An external validation on an independent test set found the SVM model had an R value of 0.96 and RMSE of 0.166, demonstrating good predictive ability.